1 / 20

Septal ablation in Hypertrophic Cardiomyopathy

Septal ablation in Hypertrophic Cardiomyopathy. Charles Knight London Chest Hospital Advanced Angioplasty 2003. Terminology. Non-surgical septal reduction (NSSR) Percutaneous transluminal septal myocardial ablation (PTSMA) Transcoronary ablation of septal hypertrophy (TASH) Septal ablation

renjiro
Download Presentation

Septal ablation in Hypertrophic Cardiomyopathy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Septal ablation in Hypertrophic Cardiomyopathy Charles Knight London Chest Hospital Advanced Angioplasty 2003

  2. Terminology • Non-surgical septal reduction (NSSR) • Percutaneous transluminal septal myocardial ablation (PTSMA) • Transcoronary ablation of septal hypertrophy (TASH) • Septal ablation • Alcohol ablation • HOCM ablation • Sigwart procedure

  3. History • 1980’s • Preliminary experiments • by Ulrich Sigwart at Laussane • Temporary balloon occlusion • of first septal artery • Injection of verapamil down • first septal artery • June 1994 • First septal ablation by Ulrich • Sigwart at Royal Brompton • 1997 • Described as ‘profoundly aggressive’ with an ‘unacceptably high mortality and morbidity’ in NEJM* *NEJM 1997;337:349

  4. Myotomy-myectomy

  5. Patient selection • No evidence for effect on prognosis • Majority of patients with HCM have no obstruction (~75%) • Majority of patients with obstruction have symptoms responsive to medical therapy • Those with obstruction and unresponsive symptoms can be treated with septal ablation or myotomy-myectomy

  6. No effect on: Underlying pathology Myocardial disarray Small coronary artery abnormalities Diastolic dysfunction Associated mitral valve abnormalities Risk of sudden death Prognosis Effect on: • Outflow tract gradient • Symptoms

  7. Procedure • Temporary pacing wire • Intermediate wire to S1 • OTW balloon inflated at origin of S1 • Wire removed, balloon inflated • 3-5ml of absolute alcohol injected • 5 minutes marination then balloon deflated

  8. Septal Ablation - Published Reports • Knight et al Circulation 1997;95:2075 18 patients • Faber et al Circulation 1998;98:2415 91 patients • Lakkis et al Circulation1998;98:1750 33 patients • Gietzen et al Eur Heart J 1999;20:1342 50 patients • Kim et al Am J Cardiol 1999;83:1220 20 patients • Qin et al J Am Coll Cardiol 2001;38:1994 25 patients • Total 237 patients Longer term (7-36 month follow-up) • Gietzen et al Eur Heart J 1999;20:1342 37 patients • Faber et al Heart 2000;83:326 25 patients • Firoozi et al Eur Heart J 2002;23:1617 20 patients • Shamin et al NEJM 2002 ;347:1326 64 patients • Total 146 patients

  9. Pre Post

  10. Effect on Outflow Gradient • All reports: • 65 mmHg pre • 5 mmHg post • Reduction in gradient sustained in long-term Shamin et al N Engl J Med 2002;347:1326

  11. Effect on Symptoms • All reports show significant improvement • Mean NYHA class pre 2.85, post 1.3 • Maintained over longer-term

  12. Effect on exercise • 3 reports assessed peak O2 consumption (n=104) • 44% improvement • 7 reports assessed exercise duration/watts (n=204) • 41% improvement • Maintained at longer-term Shamin et al N Engl J Med 2002;347:1326

  13. Mortality • Short-term: 5/303 deaths (1.7%) • 2 in patients with severe pulmonary disease • 1 pulmonary embolus (line-related DVT) • 1 sudden AV block day 4 • 1 sudden out-of hospital (?AV block) • Long-term: 1 further death (pancreatic carcinoma)

  14. Heart-Block • Overall rate is ~ 20% requiring PPM • Ranges from 0-40% • Incidence appears to be reducing (contrast echo) • 10% of surgical patients require PPM • Beneficial effects of procedure similar in paced/not paced patients* *Shamin et al N Engl J Med 2002;347:1326

  15. Arrhythmias • Early VF in 1.6% • No late arrhythmias reported

  16. Late Ventricular Dilatation • Information from 134 patients • (4 reports) • 4.2mm Pre • 4.7mm Post Shamin et al N Engl J Med 2002;347:1326

  17. Comparison with Surgery • No randomised studies • Two recent non-randomised comparisons • St George’s Hospital • Cleveland Clinic • Patients well matched but septal ablation patients older and more co-morbidity

  18. Cleveland Clinic St. George’s Firoozi et al Eur Heart J 2002;23:1617 Qin et al JACC 2001;38:1994

  19. Conclusions • Still limited data • Not profoundly aggressive • Results similar to surgery • Mortality and morbidity acceptable and similar to surgery • Should be performed as part of a HCM service by experienced operators • Patient selection of paramount importance

More Related